AstraZeneca PLC Ordinary Shares (AZN)
R&D Expense Growth
16.07%
Quarterly · Period ending:
AZN R&D Expense Growth
Latest reported16.07%period ending
Latest reported16.07%period ending
AZN Quarterly R&D Growth (QoQ) (0.00% → 16.07%)
Latest values, visible window
High-resolution chart · PNG
AZN r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 16.0653% | |
| -9.5805% | |
| 5.4327% | |
| 3.2413% | |
| 12.314% | |
| -32.4567% | |
| 50.1445% | |
| 3.5572% | |
| 8.0848% | |
| -9.437% | |
| 18.9241% | |
| -3.1121% | |
| 2.1448% | |
| -6.3486% | |
| 13.4255% | |
| -3.4564% | |
| 19.3624% | |
| -48.5404% | |
| 14.8199% | |
| 97.3756% | |
| 6.7717% | |
| -16.3574% | |
| 36.99% | |
| 7.6314% | |
| 0.072% | |
| -36.1252% | |
| 61.4413% | |
| -0.7375% | |
| 7.109% | |
| -37.0775% | |
| 61.9968% | |
| -8.8106% | |
| 6.4894% | |
| -17.5371% | |
| 10.4701% | |
| 4.0771% | |
| -7.1576% | |
| -5.8328% | |
| 10.0571% | |
| -4.3003% | |
| -1.0135% | |
| -15.2348% | |
| 22.1833% | |
| -2.5239% | |
| 8.1121% | |
| -9.5397% | |
| -3.4149% | |
| 16.8675% | |
| 10.6667% | |
| -16.0252% | |
| 66.5501% | |
| -32.7059% | |
| 1.2708% | |
| -4.6212% | |
| 9.6346% | |
| 1.2616% | |
| -22.2876% | |
| -18.0503% | |
| 44.0586% | |
| 8.1803% | |
| 3.0981% | |
| -39.7927% | |
| 79.2015% | |
| -18.4091% | |
| 33.1988% | |
| -24.5814% | |
| 24.4318% | |
| -0.2833% | |
| 8.0612% | |
| -33.3787% | |
| 16.6534% | |
| -0.3162% | |
| 7.022% | |
| -19.5371% | |
| 10.7008% | |
| 10.9532% | |
| 2.2222% | |
| 4.0925% | |
| 16.8399% | |
| 0.733% | |
| 10.9175% | |
| -1.3746% | |
| 11.7798% | |
| -9.186% | |
| -0.578% | |
| -29.9595% | |
| 50.0608% | |
| -7.3198% | |
| 3.6173% | |
| -17.7543% | |
| 29.0322% | |
| -1.2968% | |
| 4.4518% | |
| -12.6557% | |
| 20.5159% | |
| 2.9213% | |
| 3.7303% | |
| -65.2612% | |
| 226.7757% | |
| -8.2212% |